ArticleAnais brasileiros de dermatologia2019
Consensus on the treatment of autoimmune bullous dermatoses: bullous pemphigoid, mucous membrane pemphigoid and epidermolysis bullosa acquisita - Brazilian Society of Dermatology.
Article in Anais brasileiros de dermatologia, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 62 citations in OpenAlex.
- Anti-interleukin 4 receptor α antibody for the treatment of Chinese bullous pemphigoid patients with diverse comorbidities and a 1-year follow-up: a monocentric real-world study.Frontiers in immunology · 2023Trial
- Rituximab in Mucous Membrane Pemphigoid: Current Evidence and Clinical Perspectives.Healthcare (Basel, Switzerland) · 2026Article
- Targeted Therapies and Pharmacologic Advances in Mucous Membrane Pemphigoid: A Comprehensive Review.Dermatology practical & conceptual · 2025Review
- A 10-Year Observational Study on Treatment Approaches in Pemphigus and Pemphigoid.Acta stomatologica Croatica · 2025Review
- Rituximab in the Treatment of Epidermolysis Bullosa Acquisita: A Systematic Review.The Journal of clinical and aesthetic dermatology · 2024Review
- Ocular involvement in oral vesiculobullous diseases: A review on reported cases in the literature.The Saudi dental journal · 2024Review
- Analysis of a Combination Therapy Protocol for the Treatment of Oral Mucous Membrane Pemphigoid: A Retrospective Case Series Study.International journal of dentistry · 2024Article
- Autoimmunity against laminin 332.Frontiers in immunology · 2023Review
- Anti-Laminin 332-Type Mucous Membrane Pemphigoid.Biomolecules · 2022Review
- Severe bullous pemphigoid with excoriation disorder.BMJ case reports · 2022Article
- Immunoglobulin Disorders and the Oral Cavity: A Narrative Review.Journal of clinical medicine · 2022Review
- Current and Innovated Managements for Autoimmune Bullous Skin Disorders: An Overview.Journal of clinical medicine · 2022Review
- Methylprednisolone Plus Low-Dose Methotrexate for Bullous Pemphigoid-A Single Center Retrospective Analysis.Journal of clinical medicine · 2022Article
- Researching trends in pemphigoid diseases: A bibliometric study of the top 100 most cited publications.Frontiers in medicine · 2022Article
- Bullous Pemphigoid and Other Pemphigoid Dermatoses.Medicina (Kaunas, Lithuania) · 2021Review
- Epidermolysis bullosa acquisita treated with rituximab.BMJ case reports · 2021Article
- Bullous Autoimmune Dermatoses–Clinical Features, Diagnostic Evaluation, and Treatment Options.Deutsches Arzteblatt international · 2021Review
- Preventive but Not Therapeutic Topical Application of Local Anesthetics Can Inhibit Experimental Epidermolysis Bullosa Acquisita in Mice.Frontiers in immunology · 2021Article
- Bullous pemphigoid successfully treated with dupilumab.Anais brasileiros de dermatologiaArticle
- Epidermolysis bullosa acquisita.Anais brasileiros de dermatologiaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bullous pemphigoid, mucous membrane pemphigoid and epidermolysis bullosa acquisita are subepidermal autoimmune blistering diseases whose antigenic target is located at the basement membrane zone. Mucous membrane pemphigoid and epidermolysis bullosa acquisita can evolve with cicatricial mucosal involvement, leading to respiratory, ocular and/or digestive sequelae with important morbidity. For each of these dermatoses, a literature review covering all therapeutic options was performed. A flowchart, based on the experience and joint discussion among the authors of this consensus, was constructed to provide treatment orientation for these diseases in Brazil. In summary, in the localized, low-risk or non-severe forms, drugs that have immunomodulatory action such as dapsone, doxycycline among others may be a therapeutic option. Topical treatment with corticosteroids or immunomodulators may also be used. Systemic corticosteroid therapy continues to be the treatment of choice for severe forms, especially those involving ocular, laryngeal-pharyngeal and/or esophageal mucosal involvement, as may occur in mucous membrane pemphigoid and epidermolysis bullosa acquisita. Several immunosuppressants are used as adjuvant alternatives. In severe and recalcitrant cases, intravenous immunoglobulin is an alternative that, while expensive, may be used. Immunobiological drugs such as rituximab are promising drugs in this area. Omalizumab has been used in bullous pemphigoid.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.